Coordination of COVID-19 platform trials in Europe.
Adaptive platform trial
COVID-19
Coordination mechanism
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
25 Apr 2024
25 Apr 2024
Historique:
received:
19
12
2023
accepted:
18
04
2024
medline:
25
4
2024
pubmed:
25
4
2024
entrez:
24
4
2024
Statut:
epublish
Résumé
To ensure optimal coordination of the EU-funded COVID-19 platform trials, a double coordination mechanism was established. It included the Trial Coordination Board (TCB) to promote the dialogue between investigators and relevant public health stakeholders and the Joint Access Advisory Mechanism (JAAM) to streamline access of new intervention arms to the platform trials. Both the TCB and the JAAM emerged as efficient instruments to promote cooperation and optimise the use of resources within EU-funded adaptive platform trials. In addition, an adaptive platform trial toolbox was developed to collect information and literature on challenges and solutions identified to date. The recently funded 'Coordination MEchanism for Cohorts and Trials' (CoMeCT) project will endeavour to make this model sustainable, with a further expansion to other emerging infectious diseases, as part of the governance of the current and future platform trials for pandemic preparedness. This example could serve as a model for platform trial coordination in other disease areas.
Identifiants
pubmed: 38659031
doi: 10.1186/s13063-024-08126-5
pii: 10.1186/s13063-024-08126-5
doi:
Types de publication
Journal Article
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
278Subventions
Organisme : HORIZON EUROPE Health
ID : 101136531
Organisme : HORIZON EUROPE Health
ID : 101046109
Organisme : Horizon 2020
ID : 101015736
Organisme : Horizon 2020
ID : 101037867
Organisme : Horizon 2020
ID : 101003589
Informations de copyright
© 2024. The Author(s).
Références
Eichler HG, Cavaleri M, Enzmann H, et al. Clinical trials for COVID-19: can we better use the short window of opportunity? Clin Pharmacol Ther. 2020;108:730–3.
doi: 10.1002/cpt.1891
pubmed: 32407539
European Medicines Agency. Call to pool research resources into large multi-centre, multi-arm clinical trials to generate sound evidence on COVID-19 treatments. 2020. https://www.ema.europa.eu/en/news/call-pool-research-resources-large-multi-centre-multi-arm-clinical-trials-generate-sound-evidence .Accessed 31Mar 2022.
Depoortere E, Sowinski S, van Hengel A, Kerstiëns B, Norstedt I. COVID-19 kick-starts a new era for clinical trials and pandemic preparedness in Europe. Lancet Infect Dis. 2022;22:315.
doi: 10.1016/S1473-3099(22)00059-7
pubmed: 35218745
pmcid: 8865874
Goossens H, Derde L, Horby P, Bonten M. The European clinical research response to optimise treatment of patients with COVID-19: lessons learned, future perspective, and recommendations. Lancet Infect Dis 2021. https://doi.org/10.1016/S1473-3099(21)00705-2 . Published online Dec 21.
Mullard A. COVID-19 platform trial delivers. Nat Rev Drug Discov. 2020;19:501.
pubmed: 32636506
EU-Response investigators group, Diallo A, Trøseid M, et al. Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group. Clin Microbiol Infect. 2022;28:1–5.
doi: 10.1016/j.cmi.2021.10.011
Chinnery PF, Bonnet M, Cave A, et al. Choosing drugs for UK COVID-19 treatment trials. Nat Rev Drug Discov. 2022;21:81–2.
doi: 10.1038/d41573-021-00203-7
pubmed: 34876668